Literature DB >> 20074801

The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia.

Michela Tarnani1, Luca Laurenti, Pablo G Longo, Nicola Piccirillo, Stefania Gobessi, Alice Mannocci, Sara Marietti, Simona Sica, Giuseppe Leone, Dimitar G Efremov.   

Abstract

We recently reported that leukemic cells from IgVH-unmutated/progressive CLL more frequently proliferate in response to CpG-ODN stimulation than their corresponding counterparts. Here we evaluated the prognostic impact of this proliferative response in 91 CLL patients. The proliferative response was highly predictive of PFS, TTT and OS in the whole series and refined prognosis in patients with M-CLL. BCR stimulation modulated the response to CpG-ODN, suggesting that the proliferative capacity of the leukemic cells is related to antigen-encounter history. These data support the hypothesis that the capacity of the leukemic cells to respond to external stimuli influences disease progression in CLL. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20074801     DOI： 10.1016/j.leukres.2009.12.020

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  9 in total

1.  The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Authors:  Preetesh Jain; Graciela M Nogueras González; Rashmi Kanagal-Shamanna; Uri Rozovski; Nawid Sarwari; Constantine Tam; William G Wierda; Philip A Thompson; Nitin Jain; Rajyalakshmi Luthra; Andres Quesada; Gabriela Sanchez-Petitto; Alessandra Ferrajoli; Jan Burger; Hagop Kantarjian; Jorge Cortes; Susan O'Brien; Michael J Keating; Zeev Estrov
Journal:  Br J Haematol       Date:  2017-11-21       Impact factor: 6.998

2.  IGHV1 status in chronic lymphocytic leukemia identify ethnic groups with an aggressive clinical course (Comment to Giudice ID, Foà R. Haematologica. 2019;104(2):219-221).

Authors:  Teresa Amato; Massimo Granai; Lorenzo Leoncini; Cristiana Bellan
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

3.  The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.

Authors:  Francisco de Paula Careta; Stefania Gobessi; Rodrigo Alexandre Panepucci; Engin Bojnik; Fabio Morato de Oliveira; Daniel Mazza Matos; Roberto P Falcão; Luca Laurenti; Marco A Zago; Dimitar G Efremov
Journal:  Haematologica       Date:  2012-02-13       Impact factor: 9.941

4.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

5.  Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia.

Authors:  Junyan Lu; Ester Cannizzaro; Fabienne Meier-Abt; Sebastian Scheinost; Peter-Martin Bruch; Holly Ar Giles; Almut Lütge; Jennifer Hüllein; Lena Wagner; Brian Giacopelli; Ferran Nadeu; Julio Delgado; Elías Campo; Maurizio Mangolini; Ingo Ringshausen; Martin Böttcher; Dimitrios Mougiakakos; Andrea Jacobs; Bernd Bodenmiller; Sascha Dietrich; Christopher C Oakes; Thorsten Zenz; Wolfgang Huber
Journal:  Nat Cancer       Date:  2021-07-01

6.  Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells.

Authors:  Eleonora Fonte; Maria Giovanna Vilia; Daniele Reverberi; Ilenia Sana; Lydia Scarfò; Pamela Ranghetti; Ugo Orfanelli; Simone Cenci; Giovanna Cutrona; Paolo Ghia; Marta Muzio
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

7.  Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.

Authors:  David E Spaner; Robertson Venema; Justin Huang; Peter Norris; Alan Lazarus; Guizhi Wang; Yonghong Shi
Journal:  EBioMedicine       Date:  2018-08-30       Impact factor: 8.143

Review 8.  The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Authors:  Graham Packham; Serge Krysov; Alex Allen; Natalia Savelyeva; Andrew J Steele; Francesco Forconi; Freda K Stevenson
Journal:  Haematologica       Date:  2014-07       Impact factor: 9.941

9.  TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity.

Authors:  Federica Riva; Eduardo Bonavita; Elisa Barbati; Marta Muzio; Alberto Mantovani; Cecilia Garlanda
Journal:  Front Immunol       Date:  2012-10-29       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.